Benjamin W. Streeter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Benjamin W. Streeter has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Michael E. Davis
Emory University School of Medicine
5 shared publications Donald Bejleri
Wallace H Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, GA, USA
2 shared publicationsMilton E. Brown
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, 30332, United States
2 shared publications- Younan Xia
School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, Georgia 30332, United States
2 shared publications Ajit P. Yoganathan
Wallace H Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, GA, USA
1 shared publicationAline L. Y. Nachlas
Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, 1760 Haygood Dr., Atlanta, GA, 30322, USA
1 shared publication
Latest Publications
- 18 February 2022
- Published by Elsevier in Biomaterials
- Vol. 283, 121421
Using computational methods to design patient-specific electrospun cardiac patches for pediatric heart failure
- 18 February 2022
- Published by Elsevier in Biomaterials
- Vol. 283, 121421
Using computational methods to design patient-specific electrospun cardiac patches for pediatric heart failure
- 1 May 2020
- Published by Elsevier in Biomaterials
- Vol. 240, 119838
A multilayered valve leaflet promotes cell-laden collagen type I production and aortic valve hemodynamics
- 1 May 2020
- Published by Elsevier in Biomaterials
- Vol. 240, 119838
A multilayered valve leaflet promotes cell-laden collagen type I production and aortic valve hemodynamics
- 25 April 2019
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 11 (20) , 18242-18253
Electrospun Nanofiber-Based Patches for the Delivery of Cardiac Progenitor Cells
Congenital heart disease (CHD) is the number one cause of birth defect-related death because it often leads to right ventricular heart failure (RVHF). One promising avenue to combat this RVHF is the use of cardiac patches comprised of stem cells and scaffolds. Herein, we demonstrate a reparative cardiac patch by combining neonatal or child c-Kit+ cardiac progenitor cells (CPCs) with a scaffold comprised of electrospun polycaprolactone (PCL) nanofibers. We examined different parameters of the patch, including the alignment, composition, and surface properties of the nanofibers, as well as the age of the CPCs. The patch based on uniaxially aligned nanofibers successfully aligned the CPCs. With the inclusion of gelatin in the nanofiber matrix and/or coating of fibronectin on the surface of the nanofibers, the metabolism of both neonatal and child CPCs was generally enhanced. The conditioned media collected from both patches based on aligned and random nanofibers could reduce the fibrotic gene expression in rat cardiac fibroblasts following stimulation with transforming growth factor beta (TGF-β). Furthermore, the conditioned media collected from the nanofiber-based patches could lead to the formation of tubes of human umbilical vein endothelial cells, indicating the pro-angiogenic capability of the patch. Taken together, the electrospun nanofiber-based patches are a suitable delivery vehicle for CPCs and can confer reparative benefit through anti-fibrotic and pro-angiogenic paracrine signaling.
- 25 April 2019
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 11 (20) , 18242-18253
Electrospun Nanofiber-Based Patches for the Delivery of Cardiac Progenitor Cells
Congenital heart disease (CHD) is the number one cause of birth defect-related death because it often leads to right ventricular heart failure (RVHF). One promising avenue to combat this RVHF is the use of cardiac patches comprised of stem cells and scaffolds. Herein, we demonstrate a reparative cardiac patch by combining neonatal or child c-Kit+ cardiac progenitor cells (CPCs) with a scaffold comprised of electrospun polycaprolactone (PCL) nanofibers. We examined different parameters of the patch, including the alignment, composition, and surface properties of the nanofibers, as well as the age of the CPCs. The patch based on uniaxially aligned nanofibers successfully aligned the CPCs. With the inclusion of gelatin in the nanofiber matrix and/or coating of fibronectin on the surface of the nanofibers, the metabolism of both neonatal and child CPCs was generally enhanced. The conditioned media collected from both patches based on aligned and random nanofibers could reduce the fibrotic gene expression in rat cardiac fibroblasts following stimulation with transforming growth factor beta (TGF-β). Furthermore, the conditioned media collected from the nanofiber-based patches could lead to the formation of tubes of human umbilical vein endothelial cells, indicating the pro-angiogenic capability of the patch. Taken together, the electrospun nanofiber-based patches are a suitable delivery vehicle for CPCs and can confer reparative benefit through anti-fibrotic and pro-angiogenic paracrine signaling.
- 13 December 2018
- Published by Springer Nature
- Vol. 1144, 1-24
Therapeutic Cardiac Patches for Repairing the Myocardium
The explosion of stem cell research in the past several years has made its presence known in the field of cardiology and has been recently tasked with solving one of the largest health problems to afflict humanity: cardiovascular disease (CVD). Although stem cell therapy has shown glimmers of promise, significant problems remain that need to be addressed if these therapies are to ever find true success. One way to achieve this success is to take engineering principles and apply them to fabricate engineered cardiac tissues, composed of the aforementioned therapeutic stem cells and biomaterials to bolster the tissue’s reparative capacity. In this review, the authors examine advancements in cardiac cell therapy and biomaterial research and discuss how their combination has been used to create tissue-engineered patches capable of restoring function to the damaged or failing myocardium.
- 13 December 2018
- Published by Springer Nature
- Vol. 1144, 1-24
Therapeutic Cardiac Patches for Repairing the Myocardium
The explosion of stem cell research in the past several years has made its presence known in the field of cardiology and has been recently tasked with solving one of the largest health problems to afflict humanity: cardiovascular disease (CVD). Although stem cell therapy has shown glimmers of promise, significant problems remain that need to be addressed if these therapies are to ever find true success. One way to achieve this success is to take engineering principles and apply them to fabricate engineered cardiac tissues, composed of the aforementioned therapeutic stem cells and biomaterials to bolster the tissue’s reparative capacity. In this review, the authors examine advancements in cardiac cell therapy and biomaterial research and discuss how their combination has been used to create tissue-engineered patches capable of restoring function to the damaged or failing myocardium.
- 31 October 2018
- Published by Wiley in Advanced Healthcare Materials
- Vol. 7 (23) , e1800672
A Bioprinted Cardiac Patch Composed of Cardiac‐Specific Extracellular Matrix and Progenitor Cells for Heart Repair
Congenital heart defects are present in 8 of 1000 newborns and palliative surgical therapy has increased survival. Despite improved outcomes, many children develop reduced cardiac function and heart failure requiring transplantation. Human cardiac progenitor cell (hCPC) therapy has potential to repair the pediatric myocardium through release of reparative factors, but therapy suffers from limited hCPC retention and functionality. Decellularized cardiac extracellular matrix hydrogel (cECM) improves heart function in animals, and human trials are ongoing. In the present study, a 3D‐bioprinted patch containing cECM for delivery of pediatric hCPCs is developed. Cardiac patches are printed with bioinks composed of cECM, hCPCs, and gelatin methacrylate (GelMA). GelMA‐cECM bioinks print uniformly with a homogeneous distribution of cECM and hCPCs. hCPCs maintain >75% viability and incorporation of cECM within patches results in a 30‐fold increase in cardiogenic gene expression of hCPCs compared to hCPCs grown in pure GelMA patches. Conditioned media from GelMA‐cECM patches show increased angiogenic potential (>2‐fold) over GelMA alone, as seen by improved endothelial cell tube formation. Finally, patches are retained on rat hearts and show vascularization over 14 d in vivo. This work shows the successful bioprinting and implementation of cECM‐hCPC patches for potential use in repairing damaged myocardium.
- 31 October 2018
- Published by Wiley in Advanced Healthcare Materials
- Vol. 7 (23) , e1800672
A Bioprinted Cardiac Patch Composed of Cardiac‐Specific Extracellular Matrix and Progenitor Cells for Heart Repair
Congenital heart defects are present in 8 of 1000 newborns and palliative surgical therapy has increased survival. Despite improved outcomes, many children develop reduced cardiac function and heart failure requiring transplantation. Human cardiac progenitor cell (hCPC) therapy has potential to repair the pediatric myocardium through release of reparative factors, but therapy suffers from limited hCPC retention and functionality. Decellularized cardiac extracellular matrix hydrogel (cECM) improves heart function in animals, and human trials are ongoing. In the present study, a 3D‐bioprinted patch containing cECM for delivery of pediatric hCPCs is developed. Cardiac patches are printed with bioinks composed of cECM, hCPCs, and gelatin methacrylate (GelMA). GelMA‐cECM bioinks print uniformly with a homogeneous distribution of cECM and hCPCs. hCPCs maintain >75% viability and incorporation of cECM within patches results in a 30‐fold increase in cardiogenic gene expression of hCPCs compared to hCPCs grown in pure GelMA patches. Conditioned media from GelMA‐cECM patches show increased angiogenic potential (>2‐fold) over GelMA alone, as seen by improved endothelial cell tube formation. Finally, patches are retained on rat hearts and show vascularization over 14 d in vivo. This work shows the successful bioprinting and implementation of cECM‐hCPC patches for potential use in repairing damaged myocardium.